<DOC>
	<DOCNO>NCT02066415</DOCNO>
	<brief_summary>To evaluate effect AMG 334 compare placebo change baseline monthly migraine day</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety AMG 334 Chronic Migraine Prevention</brief_title>
	<detailed_description>Phase 2 , multicenter , randomize , double-blind , placebo-controlled study patient chronic migraine . Approximately 651 subject randomize receive either placebo , one two AMG 334 subcutaneous ( SC ) dose every month duration 12-week double-blind treatment phase . There also safety follow-up visit treatment phase .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>History least 5 attack migraine without aura and/or migraine visual sensory , speech and/or language , retinal brainstem aura . History ≥ 15 headache day per month ≥ 8 headache day assess subject migraine day . ≥ 4 distinct headache episode , last ≥ 4 hour OR shorter , associate use triptan ergotderivative calendar day base eDiary calculation . Demonstrated least 80 % compliance eDiary . History cluster headache hemiplegic migraine headache Unable differentiate migraine headache Failed &gt; 3 medication category due lack efficacy prophylactic treatment migraine . Received botulinum toxinin head neck region within 4 month prior screen . Used prohibited migraine prophylactic medication , device procedure within 2 month prior start baseline phase</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Chronic Migraine</keyword>
</DOC>